Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 3/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29456279 | 0.86 | MAPK8 (0.44) | MAPK8MAPK9MAPK10TDP1DGAT2 | |
| SCHEMBL20824781 | 0.80 | LOXL2 (0.40) | MAPK8MAPK9MAPK10DGAT2LOXL2 | |
| SCHEMBL3718226 | 0.79 | MTNR1A (0.42) | MAPK8MAPK9MAPK10DGAT2SLC22A12 | |
| SCHEMBL3594395 | 0.78 | TDP1 (0.56) | CXCL8TDP1KDM4EAKR1B1 | |
| SCHEMBL29091757 | 0.78 | LOXL2 (0.55) | NAPRTCXCL8TDP1LOXL2PTGDR2 | |
| SCHEMBL3711409 | 0.73 | KDM4E (0.41) | NAPRTPTGDR2KDM4EMAPT | |
| SCHEMBL28892748 | 0.73 | LOXL2 (0.40) | MAPK8MAPK9MAPK10DGAT2LOXL2 | |
| SCHEMBL3714691 | 0.72 | TDP1 (0.64) | MAPK8MAPK9MAPK10NAPRTTDP1 | |
| SCHEMBL20824748 | 0.72 | SLC6A4 (0.40) | MAPK8MAPK9MAPK10DGAT2LOXL2 | |
| SCHEMBL837578 | 0.72 | TDP1 (0.64) | MAPK8MAPK9MAPK10TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220081427-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| US-20200277285-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-20200039972-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20190194176-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20180319780-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2018-11-08 | — | — | US | disclosed |
| US-20180037577-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2018-02-08 | — | — | US | disclosed |
| EP-2393806-B1 | INHIBITORS OF JUN N-TERMINAL KINASE | ELAN PHARM INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9796706-B2 | Inhibitors of Jun N-terminal kinase | IMAGO PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170107209-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20150259330-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-9073891-B2 | Inhibitors of Jun N-terminal kinase | IMAGO PHARMACEUTICALS, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-8450363-B2 | Inhibitors of Jun N-terminal kinase | ELAN PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20130072494-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | ELAN PHARMACEUTICALS, INC. | 2013-03-21 | — | — | US | disclosed |
| EP-2393806-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | Elan Pharmaceuticals Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20100331335-A1 | Inhibitors of Jun N-Terminal Kinase | ELAN PHARMACETICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2010091310-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039972-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK8 24/4885MAPK9 16/4885MAPK10 21/4885 |
| US-20190194176-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK8 24/4885MAPK9 16/4885MAPK10 21/4885 |
| US-20150259330-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK8 24/4885MAPK9 16/4885MAPK10 21/4885 |
| US-20170107209-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK8 24/4885MAPK9 16/4885MAPK10 21/4885 |
| US-20180037577-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK8 24/4885MAPK9 16/4885MAPK10 21/4885 |
| US-20130072494-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK8 24/4885MAPK9 16/4885MAPK10 21/4885 |
| US-20220081427-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK8 24/4885MAPK9 16/4885MAPK10 21/4885 |
| US-20200277285-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK8 24/4885MAPK9 16/4885MAPK10 21/4885 |
| US-20180319780-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK8 24/4885MAPK9 16/4885MAPK10 21/4885 |
| US-20100331335-A1 | Inhibitors of Jun N-Terminal Kinase | CHUK, MAPK6, MAPK3 | MAPK8 24/4885MAPK9 16/4885MAPK10 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.